patients will be excluded from the study if they satisfy any of the following criteria at the screening visit unless otherwise stated: having become symptomatic (fever, cough, and other likely symptoms) or positive on virologic test for more than 8 days prior to hospitalization diagnosed with sars-cov-2 confirmed more than 48 hours prior to hospitalization, otherwise reconfirmed positive on repeated rt-pcr (local laboratory) or other equivalent assays within 48 hours prior to randomization having been hospitalized for more than 48 hours, or showing a worsening medical condition within 48 hours after hospitalization in the opinion of the investigator known to have received any approved or investigational covid-19 vaccines within 6 months prior to randomization. vaccination records can be self-reported by the patient if there is no recorded history known to have received any approved or investigational therapeutic agents against sars-cov-2 including convalescent plasma, monoclonal antibodies, except for remdesivir, dexamethasone, or il-6 inhibitors as a part of soc having received any investigational medicinal products within 90 days of randomization on noninvasive ventilation, eg, continuous positive airway pressure or bilevel positive airway pressure or high-flow oxygen therapy (at who-osci score 5) intubated, ventilated (invasively), on any advanced organ/life support (pressors, renal replacement therapy, ecmo), or remaining in the intensive care unit (at who-osci score 6 and 7) known to be hypersensitive or allergic to any natural or recombinant protein products inability to utilize nebulized drugs, or history of bronchospasm with inhaled medications patients with cardiac disease (new york heart association iii/iv), liver cirrhosis (>5 x upper limit of normal [uln]), on chemotherapy, dialysis patients with estimated glomerular filtration rate <30 ml/min/1.73m2, or have other debilitating condition or any other clinically significant medical condition or laboratory abnormality that, in the opinion of the investigator, would jeopardize the safety of the patient or non- covid-19 irreversible underlying condition with projected fatal course within 6 months or with high-risk of mortality female patients are pregnant or lactating, or male or female patients have a childbearing plan within 30 days prior to randomization until 90 days after the last dosing.

patients will be excluded from the study if they satisfy any of the following criteria at the screening visit unless otherwise stated: having become symptomatic (fever, cough, and other likely symptoms) or positive on virologic test for more than 8 days prior to hospitalization diagnosed with sars-cov-2 confirmed more than 48 hours prior to hospitalization, otherwise reconfirmed positive on repeated rt-pcr (local laboratory) or other equivalent assays within 48 hours prior to randomization having been hospitalized for more than 48 hours, or showing a worsening medical condition within 48 hours after hospitalization in the opinion of the investigator known to have received any approved or investigational covid-19 vaccines within 6 months prior to randomization. vaccination records can be self-reported by the patient if there is no recorded history known to have received any approved or investigational therapeutic agents against sars-cov-2 including convalescent plasma, monoclonal antibodies, except for remdesivir, dexamethasone, or il-6 inhibitors as a part of soc having received any investigational medicinal products within 90 days of randomization on noninvasive ventilation, eg, continuous positive airway pressure or bilevel positive airway pressure or high-flow oxygen therapy (at who-osci score 5) intubated, ventilated (invasively), on any advanced organ/life support (pressors, renal replacement therapy, ecmo), or remaining in the intensive care unit (at who-osci score 6 and 7) known to be hypersensitive or allergic to any natural or recombinant protein products inability to utilize nebulized drugs, or history of bronchospasm with inhaled medications patients with cardiac disease (new york heart association iii/iv), liver cirrhosis (>5 x upper limit of normal [uln]), on chemotherapy, dialysis patients with estimated glomerular filtration rate <30 ml/min/1.73m2, or have other debilitating condition or any other clinically significant medical condition or laboratory abnormality that, in the opinion of the investigator, would jeopardize the safety of the patient or non- covid-19 irreversible underlying condition with projected fatal course within 6 months or with high-risk of mortality female patients are pregnant or lactating, or male or female patients have a childbearing plan within 30 days prior to randomization until 90 days after the last dosing.

patients will be excluded from the study if they satisfy any of the following criteria at the screening visit unless otherwise stated: 1. having become symptomatic (fever, cough, and other likely symptoms) or positive on virologic test for more than 8 days prior to hospitalization 2. diagnosed with sars-cov-2 confirmed more than 48 hours prior to hospitalization, otherwise reconfirmed positive on repeated rt-pcr (local laboratory) or other equivalent assays within 48 hours prior to randomization 3. having been hospitalized for more than 48 hours, or showing a worsening medical condition within 48 hours after hospitalization in the opinion of the investigator 4. known to have received any approved or investigational covid-19 vaccines within 6 months prior to randomization. vaccination records can be self-reported by the patient if there is no recorded history 5. known to have received any approved or investigational therapeutic agents against sars-cov-2 including convalescent plasma, monoclonal antibodies, except for remdesivir, dexamethasone, or il-6 inhibitors as a part of soc 6. having received any investigational medicinal products within 90 days of randomization 7. on noninvasive ventilation, eg, continuous positive airway pressure or bilevel positive airway pressure or high-flow oxygen therapy (at who-osci score 5) 8. intubated, ventilated (invasively), on any advanced organ/life support (pressors, renal replacement therapy, ecmo), or remaining in the intensive care unit (at who-osci score 6 and 7) 9. known to be hypersensitive or allergic to any natural or recombinant protein products 10. inability to utilize nebulized drugs, or history of bronchospasm with inhaled medications 11. patients with cardiac disease (new york heart association iii/iv), liver cirrhosis (>5 x upper limit of normal [uln]), on chemotherapy, dialysis patients with estimated glomerular filtration rate <30 ml/min/1.73m2, or have other debilitating condition or any other clinically significant medical condition or laboratory abnormality that, in the opinion of the investigator, would jeopardize the safety of the patient or non- covid-19 irreversible underlying condition with projected fatal course within 6 months or with high-risk of mortality 12. female patients are pregnant or lactating, or male or female patients have a childbearing plan within 30 days prior to randomization until 90 days after the last dosing.

patients will be excluded from the study if they satisfy any of the following criteria at the screening visit unless otherwise stated: 1. having become symptomatic (fever, cough, and other likely symptoms) or positive on virologic test for more than 8 days prior to hospitalization 2. diagnosed with sars-cov-2 confirmed more than 48 hours prior to hospitalization, otherwise reconfirmed positive on repeated rt-pcr (local laboratory) or other equivalent assays within 48 hours prior to randomization 3. having been hospitalized for more than 48 hours, or showing a worsening medical condition within 48 hours after hospitalization in the opinion of the investigator 4. known to have received any approved or investigational covid-19 vaccines within 6 months prior to randomization. vaccination records can be self-reported by the patient if there is no recorded history 5. known to have received any approved or investigational therapeutic agents against sars-cov-2 including convalescent plasma, monoclonal antibodies, except for remdesivir, dexamethasone, or il-6 inhibitors as a part of soc 6. having received any investigational medicinal products within 90 days of randomization 7. on noninvasive ventilation, eg, continuous positive airway pressure or bilevel positive airway pressure or high-flow oxygen therapy (at who-osci score 5) 8. intubated, ventilated (invasively), on any advanced organ/life support (pressors, renal replacement therapy, ecmo), or remaining in the intensive care unit (at who-osci score 6 and 7) 9. known to be hypersensitive or allergic to any natural or recombinant protein products 10. inability to utilize nebulized drugs, or history of bronchospasm with inhaled medications 11. patients with cardiac disease (new york heart association iii/iv), liver cirrhosis (>5 x upper limit of normal [uln]), on chemotherapy, dialysis patients with estimated glomerular filtration rate <30 ml/min/1.73m2, or have other debilitating condition or any other clinically significant medical condition or laboratory abnormality that, in the opinion of the investigator, would jeopardize the safety of the patient or non- covid-19 irreversible underlying condition with projected fatal course within 6 months or with high-risk of mortality 12. female patients are pregnant or lactating, or male or female patients have a childbearing plan within 30 days prior to randomization until 90 days after the last dosing.